Maria Giovanna Lupo

Learn about the unique role of Lp(a) as a genetic determinant for #ASCVD risk & the importance of testing for Lp(a) levels to better understand your patients’ cardiovascular health w/ ACC's online course. ⬇️ More: bit.ly/3WmPipH #LpaAwarenessDay #KnowLpa #ACCEd

Share this #CardioSmart infographic with your patients to explain high Lp(a), why knowing levels is important, and its impact on heart health. Learn more: bit.ly/4rMSOal #KnowLpa #LpaAwarenessDay

Encourage your patients with elevated Lp(a) levels to maintain a healthy lifestyle, and make sure you also learn more about lipoprotein(a) through our educational resources: eas.to/LpaD2026 #KnowLpa #LpaAwarenessDay @fhpatienteurope

The International Study on the cost-effectiveness of Lp(a) testing shows that using Lp(a) to reclassify cardiovascular disease (CVD) risk in the primary prevention population aged 40–69 years is a highly cost-effective way to prevent CVD. Implementing Lp(a) testing is not only strongly justified from a clinical perspective, but is also likely to deliver a financial return on investment when considered from a societal perspective. These results support the immediate implementation of Lp(a) testing in primary prevention populations in high-income countries. Learn more about this study and other Lp(a)-related initiatives here: eas.to/LpaD2026 #KnowLpa #LpaAwarenessDay @fhpatienteurope

Join us in a shared mission to raise awareness, expand understanding, and drive meaningful change in health outcomes related to Lp(a). On the occasion of Lp(a) Awareness Day, we have brought together key resources and learning opportunities to inform, inspire, and empower you: eas.to/LpaD2026 @fhpatienteurope #KnowLpa #LpaAwarenessDay

The discourse on Lp(a) among many stakeholders across the globe (medical societies, healthcare professionals, academics/researchers, patient organisations and life sciences industry) points to the urgent need to encourage a more systematic and structured approach to testing the population, following guidelines, to decrease the overall cardiovascular disease (CVD) risk / prevent CVD from high levels of Lp(a). Recommendations and guidelines such as the EAS Lipoprotein(a) 2022 Consensus Statement underline that everyone should be tested once in a lifetime. #KnowLpa #LpaAwarenessDay @fhpatienteurope

This webinar will explore how healthy, sustainable dietary patterns can help prevent cardiovascular disease (CVD), while also introducing the rapidly evolving field of precision nutrition for cardiometabolic health. Join leading experts as they share the latest research and practical strategies for improving heart health through diet: eas.to/WebDiet3

The new AtheroTalk episode is out! We were honored to host Prof. John J.P. Kastelein, one of the most influential figures in lipidology and cardiovascular prevention. With a career spanning decades of groundbreaking research and innovation, Prof. Kastelein shares his personal journey and reflects on the evolution of lipid-lowering therapy — from the early days of statins to today’s rapidly expanding pipeline of novel therapeutics. Together, we explore the milestones that have shaped modern cardiovascular prevention, the lessons learned along the way, and the exciting future of precision lipid management. This conversation offers unique insights into the intersection of science, clinical practice, and drug development, from someone who has been at the forefront of it all. 🎧 Spotify: eas.to/ATHTalkE29S 🎧 Apple Podcasts: eas.to/ATHTalkE29A 🎧 Youtube: eas.to/ATHTalkE29Y

#AtheroTalk Podcast by EAS Young Fellows is One of the new activities the EAS President prof Børge Nordestgaard is most proud of!! Very happy to be part of this!!! We rock!!!!! #EASCongress2025 @society_eas @EASCongress